Send to

Choose Destination
Biosocieties. 2017 Jun;12(2):217-238. doi: 10.1057/biosoc.2015.46. Epub 2017 Jun 28.

White opioids: Pharmaceutical race and the war on drugs that wasn't.

Author information

Drug Policy Alliance, 330 Seventh Avenue, New York, NY 10001, USA.
Departments of Anthropology and Psychiatry, New York University, New York, NY 10003, USA.
Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY10962, USA.


The US 'War on Drugs' has had a profound role in reinforcing racial hierarchies. Although Black Americans are no more likely than Whites to use illicit drugs, they are 6-10 times more likely to be incarcerated for drug offenses. Meanwhile, a very different system for responding to the drug use of Whites has emerged. This article uses the recent history of White opioids - the synthetic opiates such as OxyContin® that gained notoriety starting in the 1990s in connection with epidemic prescription medication abuse among White, suburban and rural Americans and Suboxone® that came on the market as an addiction treatment in the 2000s - to show how American drug policy is racialized, using the lesser known lens of decriminalized White drugs. Examining four 'technologies of whiteness' (neuroscience, pharmaceutical technology, legislative innovation and marketing), we trace a separate system for categorizing and disciplining drug use among Whites. This less examined 'White drug war' has carved out a less punitive, clinical realm for Whites where their drug use is decriminalized, treated primarily as a biomedical disease, and where their whiteness is preserved, leaving intact more punitive systems that govern the drug use of people of color.


addiction; heroin; prescription opioids; whiteness

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center